SDGR · Schrodinger, Inc. · Executive Compensation
$23.56
-2.78 (-10.55%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$1.98B
Shares
75.08M
Volume · Nov 20
724.01K
Avg daily vol (3M)
2.05M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Ramy Farid | President and Chief Executive Officer | $4,079,043 |
| Karen Akinsanya | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | $2,110,924 |
| Geoffrey Porges | Chief Financial Officer | $2,021,911 |
| Mannix Aklian | Chief Commercial Officer, Global Head of Software Sales & Marketing | $2,011,376 |
| Yvonne Tran | Chief Legal Officer and Chief People Officer | $1,800,806 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Ramy Farid | President and Chief Executive Officer | $4,407,100 |
| Karen Akinsanya | President of R&D, Therapeutics | $2,736,718 |
| Geoffrey Porges | Chief Financial Officer | $2,392,361 |
| Robert Abel | Chief Scientific Officer, Platform | $2,131,891 |
| Patrick Lorton | Chief Operating Officer, Software and Chief Technology Officer | $2,131,891 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Margaret Dugan | Chief Medical Officer | $3,150,615 |
| Ramy Farid | President and Chief Executive Officer | $3,124,165 |
| Robert Abel | Chief Scientific Officer, Platform | $1,697,704 |
| Karen Akinsanya | President of R&D, Therapeutics | $1,680,400 |
| Geoffrey Porges | Chief Financial Officer | $1,651,742 |
| Patrick Lorton | Chief Operating Officer, Software and Chief Technology Officer | $1,443,345 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Ramy Farid | President and Chief Executive Officer | $3,916,032 |
| Geoffrey Porges | Chief Financial Officer | $3,253,875 |
| Karen Akinsanya | President of R&D, Therapeutics | $1,848,320 |
| Yvonne Tran | Chief Legal Officer | $1,473,084 |
| Robert Abel | Chief Scientific Officer, Platform | $1,465,180 |
| Patrick Lorton | Chief Operating Officer, Software and Chief Technology Officer | $1,459,644 |
| Jenny Herman | Senior Vice President, Finance and Corporate Controller | $923,129 |
| Joel Lebowitz | Former Chief Financial Officer | $446,526 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Ramy Farid | President and Chief Executive Officer | $8,493,477 |
| Karen Akinsanya | President of R&D, Therapeutics | $4,649,715 |
| Robert Abel | Chief Scientific Officer, Platform | $4,500,185 |
| Patrick Lorton | Chief Technology Officer | $4,494,505 |
| Yvonne Tran | Chief Legal Officer | $2,647,568 |
| Joel Lebowitz | Former Chief Financial Officer | $2,586,508 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Ramy Farid | President and Chief Executive Officer | $8,510,593 |
| Yvonne Tran | Chief Legal Officer | $2,375,726 |
| Karen Akinsanya | President, R&D Therapeutics | $2,330,926 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Ramy Farid | President and Chief Executive Officer | $633,101 |
| Yvonne Tran | Executive Vice President and Chief Legal Officer | $549,501 |
| Karen Akinsanya | President, R&D Therapeutics | $440,701 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Gary Sender | Class III director | Appointed | 2026-06-23 |
| Rosana Kapeller-Libermann | Class III director | Appointed | 2026-06-23 |
| Richard A. Friesner | Class III director | Appointed | 2026-06-23 |
| Paul Davie | interim Chief Commercial Officer, Global Head of Software Sales and Marketing | Appointed | 2026-05-20 |
| Therese Abrams | principal accounting officer | Appointed | 2026-03-12 |
| Richie Jain | Executive Vice President and Chief Financial Officer and Treasurer | Appointed | 2025-05-20 |
| Bridget van Kralingen | member of the Board | Appointed | 2025-03-10 |
| Arun Oberoi | Class I director | Appointed | 2024-06-18 |
| Gary Ginsberg | Class I director | Appointed | 2024-06-18 |
| Ramy Farid | Class I director | Appointed | 2024-06-18 |
| Geoffrey Porges | Executive Vice President and Chief Financial Officer | Appointed | 2022-08-18 |
| Nancy A. Thornberry | Class II directors of the Board | Appointed | 2022-06-16 |
| Michael Lynton | Class II directors of the Board | Appointed | 2022-06-16 |
| Jeffrey Chodakewitz | Class II directors of the Board | Appointed | 2022-06-16 |
| Arun Oberoi | member of the Board | Appointed | 2022-05-19 |
| Joel Lebowitz | Chief Financial Officer and Treasurer | Retired | 2022-03-02 |
| Jenny Herman | interim principal financial officer | Appointed | 2021-12-21 |
| Joel Lebowitz | Chief Financial Officer | Retired | 2021-12-21 |
Leadership
- Jenny Herman CFO
- Patrick Lorton CTO
- Therese Abrams Chief Accounting Officer
- Arun Oberoi Board Member
- Bridget van Kralingen Board Member
- Gary Ginsberg Board Member
- Gary Sender Board Member
- Jeffrey Chodakewitz Board Member
- Michael Lynton Board Member
- Nancy A. Thornberry Board Member
- Ramy Farid Board Member
- Richard A. Friesner Board Member
- Rosana Kapeller-Libermann Board Member
Key facts
CIK
1490978
CUSIP
80810D103
13F (30d)
283 filings
254 filers
Visit website
Investor relations